Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 29.50 |
| Open | 29.90 |
| Bid | 29.50 x N/A |
| Ask | 30.00 x N/A |
| Day's Range | 29.00 - 30.00 |
| 52 Week Range | 4.72 - 33.00 |
| Volume | 468,907 |
| Avg. Volume | 2,716,418 |
| Market Cap | 196.804M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.20 |
| Earnings Date | Sep 30, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
Yahoo FinanceCoronavirus update: Biden administration increases vaccine doses to states; UK approves first human challenge trial
Federal government increasing state allotment of vaccines. Meanwhile, U.K. begins first human challenge trials.
- Business Wire
Ethics Approval Granted for Open Orphan’s COVID-19 Human Challenge Study Model
Open Orphan (AIM:ORPH) announced the world’s first COVID-19 characterization study has received ethics approval in the UK.
- Yahoo Finance
Coronavirus update: US hits 1M shots per day average as scientists eye second generation COVID-19 vaccines
Scientists are studying booster shots and/or new vaccines that can protect against the evolving virus or specific strains as coronavirus variants spread around the globe.
© 2021 Verizon Media. All rights reserved.
